Navigation Links
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
Date:5/29/2009

Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration ("FDA") for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including our ability to successfully complete the clinical trials required for us to file a new drug application for CPP-109, our ability to complete such trials on a timely basis within the budgets we establish for such trials, our ability to protect our intellectual property, our ability to continue to list our common stock on the NASDAQ Global Market or to list our common stock on the NASDAQ Capital Market and those other factors described in the Company's Annual Report on Form 10-K for 2008 and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 that the Company has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the S
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
(Date:5/30/2015)... 2015 Wixom, Michigan: Proof. Pest Control, a family-owned ... a new twist to its robust line of services-a ... used for general pest management. , “We like ... Wixom Branch Manager. “The average person cringes when they see ... with problems that most people don’t even want to think ...
(Date:5/30/2015)... “ Milli the Snail ” was featured on NewsWatch as ... the latest and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... children. , Interactive mobile games for children have become quite ... they are playing are doing much for their intellectual development. ...
(Date:5/29/2015)... 2015 “In the current environment ... federal regulations, we provide education that will help ... are suffering from pain, within the boundaries of ... professor of rehabilitation medicine and President/Medical Director of ... Kansas. , A new flight of PAINWeekEnd Regional ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... May 29, 2015 The science of ... last decade. New and more efficient methods of FUE hair ... balding patients. One of the most cutting edge hair transplant ... Restoration is the technique of extracting hair from the beard ... are performed to correct male pattern baldness. Beard ...
Breaking Medicine News(10 mins):Health News:Proof. Pest Control-Now Offering 100% Organic Pest Control in Southeast Michigan 2Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2
... Sept. 4 Should doctors be,involved in the ... of Mayo Clinic Proceedings, three anesthesiologists and a,medical ... in a commentary and,two editorials., None of ... the authors explore the current position of the,American ...
... the first public,test of voter reaction to the healthcare ... Speaker Fabian Nunez, California voters,are expressing serious reservations about ... released today by the California Nurses Association. More ... 68 percent to,25 percent -- said they prefer "making ...
... Charlottesville, Va., September 4, 2007 A University of ... from the National Institute of Allergy and Infectious Diseases ... Richard Guerrant, founder of UVas Center for Global Health, ... bacterium Clostridium difficile, which is growing increasingly resistant to ...
... homes of common allergens, OMAHA, Neb., Sept. 4 ... getting bombarded by contaminants and,allergens, such as dust mites, animal ... air-tight that any air that gets in --,good or bad ... all the more important. Try to prevent as many ...
... ABT ),will present at the Bear Stearns 20th ... Freyman, executive vice president,finance and chief financial officer, will ... Central time. A live audio webcast of the ... at http://www.abbottinvestor.com . An,archived edition of the presentation ...
... NORTH ADAMS, Mass., Sept. 4 The National ... has joined its,Corporate Council as an Associate Member. ... health care products and services companies to,work along ... and patients and their families with a single ...
Cached Medicine News:Health News:Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment 2Health News:Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment 3Health News:New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8 2Health News:UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria 2Health News:Clean to Ease Allergy and Asthma Symptoms 2Health News:National Patient Safety Foundation Partners with Vocera Communications 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
... The Vitek is a completely automated instrument ... of 2 - 6 hour same day ... quality control module. It is used for ... and urine screening and has a complete ...
IDS Rapid One, a microbial identification system....
Medicine Products: